SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

被引:0
|
作者
Schmidt, Timothy [1 ]
Gahvari, Zhubin [1 ]
Callander, Natalie S. [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Hematol Med Oncol & Palliat Care, Madison, WI USA
关键词
MGUS; MM; Risk stratification; Screening; SMM; INDEPENDENT RISK-FACTOR; LIGHT-CHAIN RATIO; MASS-SPECTROMETRY; BONE-MARROW; PROGRESSION; MGUS; LENALIDOMIDE; PREVALENCE; ABNORMALITIES; POPULATION;
D O I
10.1016/j.clml.2024.03.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Monoclonal proteins are common, with a prevalence in the United States around 5% and the incidence increases with age. Although most patients are asymptomatic, the vast majority of cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma (MM). In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma. In this review, we summarize the current diagnosis treatment guidelines for MGUS and SMM and highlight recent advances that underscore a shifting paradigm in the evaluation and management of plasma cell precursor conditions.
引用
收藏
页码:653 / 664
页数:12
相关论文
共 50 条
  • [1] Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma
    Schmidt, Timothy M.
    Callander, Natalie S.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (12): : 1720 - U74
  • [2] Management of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
    Kyle, Robert A.
    Buadi, Francis
    Rajkumar, S. Vincent
    ONCOLOGY-NEW YORK, 2011, 25 (07): : 578 - 586
  • [3] Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    Rajkumar, S. Vincent
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (05) : 453 - 454
  • [4] Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
    Kyle, Robert A.
    San-Miguel, Jesus F.
    Mateos, Maria-Victoria
    Rajkumar, S. Vincent
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (05) : 775 - +
  • [5] Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    van de Donk, N. W. C. J.
    Mutis, T.
    Poddighe, P. J.
    Lokhorst, H. M.
    Zweegman, S.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 : 110 - 122
  • [6] Monoclonal gammopathy of undetermined significance and smoldering myeloma (SMM): a practical guide to management
    Maciocia, Nicola
    Wechalekar, Ashutosh
    Yong, Kwee
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 432 - 439
  • [7] Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)
    Ho, Matthew
    Patel, Ashish
    Goh, Chia Yin
    Moscvin, Maria
    Zhang, Li
    Bianchi, Giada
    LEUKEMIA, 2020, 34 (12) : 3111 - 3125
  • [8] Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma
    Bogun, Lucienne
    Koch, Annemarie
    Scherer, Bo
    Fenk, Roland
    Maus, Uwe
    Bormann, Felix
    Koehrer, Karl
    Petzsch, Patrick
    Wachtmeister, Thorsten
    Zukovs, Romans
    Dietrich, Sascha
    Haas, Rainer
    Schroeder, Thomas
    Jaeger, Paul
    Geyh, Stefanie
    BLOOD ADVANCES, 2024, 8 (10) : 2575 - 2588
  • [9] Monoclonal Gammopathy of Undetermined Significance Versus Smoldering Myeloma: Is Active Surveillance Enough?
    Jordan, W. Edward, III
    Emmons, Robert
    Vogl, Daniel
    Morris, Gloria J.
    SEMINARS IN ONCOLOGY, 2011, 38 (03) : 327 - 334
  • [10] Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions
    Ferla, Valeria
    Farina, Francesca
    Perini, Tommaso
    Marcatti, Magda
    Ciceri, Fabio
    PHARMACEUTICALS, 2024, 17 (07)